Tempus AI (NASDAQ:TEM) Research Coverage Started at Roth Capital

Roth Capital initiated coverage on shares of Tempus AI (NASDAQ:TEM) in a report published on Tuesday morning,Benzinga reports. The brokerage issued a neutral rating and a $67.00 target price on the stock.

A number of other brokerages also recently weighed in on TEM. Stifel Nicolaus lowered their price target on Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a research report on Monday, August 3rd. Wolfe Research started coverage on Tempus AI in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. HC Wainwright reduced their target price on Tempus AI from $64.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Raymond James Financial set a $80.00 target price on Tempus AI in a report on Wednesday, September 2nd. Finally, Cantor Fitzgerald began coverage on Tempus AI in a research note on Wednesday, September 2nd. They issued an “overweight” rating and a $80.00 price target on the stock. Eleven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Tempus AI presently has an average rating of “Hold” and a consensus price target of $68.78.

Tempus AI Stock Performance

Shares of TEM stock opened at $58.74 on Tuesday. The company has a fifty day moving average price of $55.99 and a two-hundred day moving average price of $52.28. Tempus AI has a one year low of $40.77 and a one year high of $104.32. The stock has a market cap of $10.60 billion, a P/E ratio of -40.79 and a beta of 3.72. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same period in the previous year, the business earned ($0.22) EPS. Tempus AI’s revenue for the quarter was up 21.6% compared to the same quarter last year. As a group, equities analysts predict that Tempus AI will post -1.38 EPS for the current year.

Insider Activity at Tempus AI

In other news, Director Nadja West sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $69.00, for a total value of $207,000.00. Following the transaction, the director owned 31,981 shares of the company’s stock, valued at approximately $2,206,689. This represents a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Rogers sold 26,313 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total value of $1,578,780.00. Following the transaction, the chief financial officer owned 106,024 shares in the company, valued at approximately $6,361,440. This trade represents a 19.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 1,043,988 shares of company stock valued at $56,963,417. Insiders own 24.26% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPL Wealth Management LLC acquired a new stake in shares of Tempus AI during the third quarter worth $26,000. Los Angeles Capital Management LLC acquired a new position in shares of Tempus AI in the fourth quarter valued at about $27,000. EMC Capital Management bought a new position in Tempus AI during the second quarter worth about $29,000. Harvest Fund Management Co. Ltd bought a new position in Tempus AI during the third quarter worth about $38,000. Finally, Whittier Trust Co. increased its position in Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after acquiring an additional 570 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus AI secured up to $9.5 million in ARPA-H funding to develop and deploy an autonomous cardiology AI agent. The award could validate Tempus’ technology, expand its healthcare partnerships and support future commercial opportunities. Tempus AI Secures Up To $9.5 Million in US Agency Funding for Cardiology Agent
• Positive Sentiment: ARPA-H plans to invest approximately $62 million across six teams developing FDA-authorized agentic AI systems for cardiovascular care. Tempus’ participation places it in a potentially high-profile government-backed initiative targeting heart-failure treatment. ARPA-H to invest $62 million to develop FDA-authorized AI to help treat heart failure

About Tempus AI

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.